Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Therapist Debby Parker tried to lose weight for years without success. Then she discovered an online weight management ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly ...

Her departure comes as the snacks maker faces challenges including higher cocoa costs, inflation that has curtailed product demand and the proliferation of GLP-1 weight-loss drugs.